The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus, was emerged in Wuhan, China, in December 2019. On March 11^th^, the World Health Organization (WHO) declared the outbreak of coronavirus disease 2019, and termed "COVID-19," a pandemic. At that point, there were 118,000 confirmed cases and 4,291 victims worldwide [@B01]. Since then, researchers around the world have been analyzing the genetic structure, multiplication patterns and the cellular mechanisms of SARS-CoV-2 *in vitro* and *in vivo* to identify possible drug targets [@B02].

Four months after the onset of the outbreak, physicians from different countries and laboratories have proposed several empirical treatments for COVID-19. To date, there are over 335 COVID-19--related clinical trials registered on the National Institutes of Health (NIH) website [@B03]. The proposed drugs aim to prevent viral entry into host cells, interrupt viral replication, and attenuate virus-induced inflammatory responses. Examples of the drugs being tested for each of these mechanisms are recombinant human angiotensin converting enzyme 2 (RhACE2), the antiviral remdesivir, and the immunosuppressant, tocilizumab, respectively.

However, the most promising drugs appear to be old drugs, the antimalarial and immunomodulatory medication, chloroquine and its hydroxy analog, hydroxychloroquine. Chloroquine and hydroxychloroquine are by far the most popular drugs proposed for treatment and prophylaxis, appearing in 97 of the COVID-19 clinical trials registered on the NIH site. These aminoquinolines, which were discovered in 1934 and are inexpensively produced in several countries, and have well-known pharmacokinetic and pharmacodynamic properties. The antiviral mechanisms of chloroquine are based on its capacity to increase the endosomal pH. This prevents enveloped viruses, such as those belonging to the *Coronaviridae* family (*e.g.*, SARS-CoV-2), from entering and releasing their genetic material into the host cells and from replicating their envelopes. Furthermore, in severe and complicated COVID-19 cases, the anti-inflammatory effects of chloroquine/hydroxychloroquine may also be of importance, as both medications can suppress the production and release of tumor necrosis factor (TNF) and interleukin 6 (IL-6) [@B04].

While the mechanisms of action of chloroquine/hydroxychloroquine are well-established, so are the side effects. Serious retinopathies and cardiopathies associated with bioaccumulation of the drugs are described in literature [@B05]. One study at the Clinics Hospital of the University of São Paulo evaluated 350 patients with systemic lupus erythematosus who were treated with chloroquine. The prevalence of side effects was 35.7%, with the most common being ocular alterations (17%), followed by gastrointestinal symptoms (10%), and dermatological (3.4%), neuromuscular (1.7%), and psychiatric alterations (0.3%) [@B06]. In Brazil, a phase 2 clinical trial on COVID-19 sponsored by the state of Amazonas was suspended after 25% of patients developed QT prolongation (\>500 m/s) owing to cardiotoxicity [@B07].

Although chloroquine/hydroxychloroquine might yield promising results, they should not be announced as a cure by politicians and the mass media, as they have never been tested as treatments for *Coronaviridae* viruses. Clinical trials are ongoing during the course of this pandemic, yet no scientific evidence has been found to support the widespread use of these medications. [Table 1](#t01){ref-type="table"} lists a few trials in advanced phases that have randomized allocation, double masking, and significant numbers of proposed participants. However, none of them have reported results as of yet.

Recent declarations by the President of Brazil recommending the indiscriminate use of chloroquine resulted in a shortage of the drug in several cities [@B08]. Aside from the lack of evidence supporting his proclamations, the president\'s action hampered the treatment of patients who truly need chloroquine for systemic lupus erythematosus and rheumatoid arthritis. Pronouncements by the French president also appeared to have pressurized French doctors to prescribe the drug, despite its unconfirmed efficacy and many possible side effects [@B09]. The same situation occurred in the United States (USA); the country\'s president has endorsed chloroquine in a highly politicized debate over its use [@B10].

A serious health system should not encourage protocols based on political beliefs or case reports. Scientific trial phases exist and are in constant review so we can guarantee some basic level of safety regarding prescription medications. Ignoring or skipping these phases can result in manmade medical disasters, such as the thalidomide-induced teratogenesis tragedies in the 20th century, which resulted in more than 10,000 children were born with debilitating malformations, leading to the scientific community being forced to rethink interventional studies and the approval process for new drugs [@B11]. Drug repositioning is possible and encouraged in case of pandemics, but chloroquine/hydroxychloroquine should not be recommended to the general population as if these medications were supported by grade 1a evidence [@B12]. Affirmations of the drugs\' effectiveness, such as those by some of our world leaders in the middle of the pandemic will only spread fear and the erroneous belief in chloroquine/hydroxychloroquine as a panacea.

In summary, there are still no effective treatments for COVID-19. Though chloroquine/hydroxychloroquine may be promising, their use should be restricted to ongoing clinical trials until we have enough evidence to recommend it to the general population. We must consider the long-term consequences of chloroquine/hydroxychloroquine administration and respect the scientific approach. A well-established, evidence-based health care policy may save more lives than a swift implementation of unsupported recommendations.
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Ongoing randomized, double-blind clinical trials on the therapeutic and prophylactic use of chloroquine/hydroxychloroquine in COVID-19 patients.

                                               NCT NUMBER      COUNTRY                                               INTERVENTION                                                         STUDY PHASE   NUMBER ENROLLED
  -------------------------------------------- --------------- ----------------------------------------------------- -------------------------------------------------------------------- ------------- -----------------
  Clinical Trials for Treatment of COVID19     NCT04342221     Germany                                               Hydroxychloroquine                                                   Phase 3       220
  NCT04329923                                  United States   Hydroxychloroquine                                    Phase 2                                                              400           
  NCT04340544                                  Germany         Hydroxychloroquine                                    Phase 3                                                              2700          
  NCT04333654                                  United States   Hydroxychloroquine and SAR321068                      Phase 1                                                              210           
  NCT04315896                                  Mexico          Hydroxychloroquine                                    Phase 3                                                              500           
  NCT04308668                                  United States   Hydroxychloroquine                                    Phase 3                                                              3000          
  NCT04329611                                  Canada          Hydroxychloroquine                                    Phase 3                                                              1660          
  NCT04332991                                  United States   Hydroxychloroquine                                    Phase 3                                                              510           
  NCT04325893                                  France          Hydroxychloroquine                                    Phase 3                                                              1300          
                                               NCT04331834     Spain                                                 Hydroxychloroquine                                                   Phase 3       440
  Clinical Trials for Prophylaxis of COVID19   NCT04334928     Spain                                                 Emtricitabine/Tenofovir Disoproxil, Hydroxychloroquine and Placebo   Phase 3       4000
  NCT04341441                                  United States   Hydroxychloroquine                                    Phase 3                                                              3000          
  NCT04336748                                  Austria         Hydroxychloroquine                                    Phase 3                                                              440           
  NCT04334148                                  United States   Hydroxychloroquine and Placebo                        Phase 3                                                              15000         
  NCT04328467                                  United States   Hydroxychloroquine                                    Phase 3                                                              3500          
  NCT04328285                                  France          Hydroxychloroquine, Lopinavir/Ritonavir and Placebo   Phase 3                                                              1200          
  NCT04303507                                  United States   Chloroquine/Hydroxychloroquine                        Not applicable                                                       40000         

Legend: COVID-19 = coronavirus disease 2019; NTC= National Clinical Trial.
